[CLSTR]
API
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 7 sources · 2 days · First seen · Last updated

Biotechnology sector quarterly earnings

Overview

The biotechnology sector reported varied quarterly financial results. Regeneron announced a 36% year-over-year revenue increase to $5.1 billion, driven by sales of Dupixent and EYLEA HD, alongside positive early clinical trial data for a gene-silencing therapy.

Amgen reported a 10% year-over-year revenue increase to $10.1 billion for its second quarter. The company is transitioning toward newer therapies like Tezspire and Imdelltra to offset upcoming patent expirations and declining sales in older immunology medicines.

Entities

Regeneron Pharmaceuticals · Amgen · LIBTAYO · Sanofi · EYLEA HD

Timeline

  1. [BUSINESS] 2 sources
    Amgen reports 10% revenue growth in second quarter

    Amgen reported a 10% increase in second-quarter revenue to $10.1 billion, driven by a diversified portfolio of high-growth biotech products.

  2. [BUSINESS] 6 sources
    Regeneron reports 36% revenue growth in third quarter

    Regeneron reported $5.1 billion in Q3 2026 revenue, a 36% year-over-year increase driven by Dupixent and EYLEA HD sales.

Sources

ad-hoc-news.de · businessdiary.com.ph · finanzen.at · finanzen.net · finanznachrichten.de · seekingalpha.com · theascent.com